<> "The repository administrator has not yet configured an RDF license."^^ . <> . . . "Combining Poly-(ARD-Ribose) Polymerase and Programmed Cell Death Protein 1 Inhibition in a Patient with Esophagogastric Adenocarcinoma"^^ . "Introduction: Esophagogastric adenocarcinoma (EGA) is one of the leading causes of cancer-related mortality worldwide. Therapeutic options are limited for patients with recurrent or metastatic disease. Targeted therapy may be a suitable treatment for selected patients, but its efficacy remains elusive. Case Presentation: Here, a 52-year-old male patient with advanced EGA Siewert Type II shows a significant response to combination therapy with olaparib and pembrolizumab. After progression following first- and second-line therapy, including a programmed cell death ligand 1 (PD-L1) inhibitor, next-generation sequencing of a tumor sample was performed to identify possible molecular targets. A mutation in RAD51C, a member of the homology-directed repair (HDR) system, was identified in addition to high PD-L1 expression. As a result, therapy with the poly-(ARD-Ribose) polymerase (PARP) inhibitor olaparib and the programmed cell death protein 1 (PD1)-inhibitor pembrolizumab was initiated. A durable partial response lasting for more than 17 months was observed. A second molecular profiling from a newly occurring subcutaneous metastasis showed a loss of FGF10 but no fluctuations in the gene alteration of RAD51C and SMARCA4. Interestingly, the new lesion showed HER2-positivity (immunohistochemistry 3+ and fluorescence in situ hybridization [FISH]-positivity) in 30% of tumor cells. Conclusion: In this case, a long-lasting response to the combination of olaparib and pembrolizumab was observed despite previous treatment with a PD-L1 inhibitor. This case illustrates the need for further clinical trials to analyze the efficacy of PARP inhibitor combinations in EGA."^^ . "2023" . . . "46" . "7-8" . . "S. Karger AG, Medical and Scientific Publishers"^^ . . . "Oncology Research and Treatment"^^ . . . "2296527022965262" . . . . . . . . . . . . . . . . . . . . . "Joseph"^^ . "Tintelnot"^^ . "Joseph Tintelnot"^^ . . "Jule Cecilia"^^ . "Artzenroth"^^ . "Jule Cecilia Artzenroth"^^ . . "Alexander"^^ . "Stein"^^ . "Alexander Stein"^^ . . "Eray"^^ . "Gökkurt"^^ . "Eray Gökkurt"^^ . . "Georg Martin"^^ . "Haag"^^ . "Georg Martin Haag"^^ . . "Johann"^^ . "Steffens"^^ . "Johann Steffens"^^ . . . . . . "Combining Poly-(ARD-Ribose) Polymerase and Programmed Cell Death Protein 1 Inhibition in a Patient with Esophagogastric Adenocarcinoma (PDF)"^^ . . . "ORT530801.pdf"^^ . . . "Combining Poly-(ARD-Ribose) Polymerase and Programmed Cell Death Protein 1 Inhibition in a Patient with Esophagogastric Adenocarcinoma (Other)"^^ . . . . . . "indexcodes.txt"^^ . . . "Combining Poly-(ARD-Ribose) Polymerase and Programmed Cell Death Protein 1 Inhibition in a Patient with Esophagogastric Adenocarcinoma (Other)"^^ . . . . . . "lightbox.jpg"^^ . . . "Combining Poly-(ARD-Ribose) Polymerase and Programmed Cell Death Protein 1 Inhibition in a Patient with Esophagogastric Adenocarcinoma (Other)"^^ . . . . . . "preview.jpg"^^ . . . "Combining Poly-(ARD-Ribose) Polymerase and Programmed Cell Death Protein 1 Inhibition in a Patient with Esophagogastric Adenocarcinoma (Other)"^^ . . . . . . "medium.jpg"^^ . . . "Combining Poly-(ARD-Ribose) Polymerase and Programmed Cell Death Protein 1 Inhibition in a Patient with Esophagogastric Adenocarcinoma (Other)"^^ . . . . . . "small.jpg"^^ . . "HTML Summary of #35301 \n\nCombining Poly-(ARD-Ribose) Polymerase and Programmed Cell Death Protein 1 Inhibition in a Patient with Esophagogastric Adenocarcinoma\n\n" . "text/html" . . . "610 Medizin"@de . "610 Medical sciences Medicine"@en . .